Ranok Therapeutics to Present at BMO Biopharma Spotlight Series on Protein Degraders and Other Next Gen Technologies

On February 15, 2022 Ranok Therapeutics, a clinical-stage biopharmaceutical company that is developing a novel approach to targeted protein degradation for the treatment of cancer and other serious diseases, reported that Kevin P. Foley, Ph.D., Co-founder and Chief Scientific Officer of Ranok, will present at the virtual BMO BioPharma Spotlight Series: Proteins – Degraders and Other Next Gen Technologies on Thursday, February 24th at 10:10 AM ET (Press release, Ranok Therapeutics, FEB 15, 2022, View Source [SID1234608143]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Foley will review the company’s strategic vision and its first clinical program, RNK05047, a first-in-class, small-molecule, BRD4-selective protein degrader which was discovered and developed using Ranok’s proprietary approach to targeted protein degradation, CHAMP (Chaperone-mediated Protein Degradation). This technology leverages the company’s expertise in protein homeostasis and the cellular chaperone network to degrade disease-associated proteins, and is designed to increase drug safety and efficacy through selective targeting of disease tissues. The U.S. Food and Drug Administration (FDA) has cleared the company’s investigational new drug application (IND) for RNK05047 and enrollment of the Phase 1/2 study for patients with advanced solid tumors and lymphomas is expected to begin in the first half of 2022.

Following the presentation, a recording will be available for 3 months on Ranok’s website at: View Source